Mifepristone in Children With Refractory Cushing's Disease

Status Withdrawn

Clinical Trial Summary

Study objectives are to obtain safety, pharmacokinetic, and pharmacodynamic data on the effect of mifepristone on glucose metabolism, body weight and the growth-hormone-IGF in children with refractory Cushing's disease.

Clinical Trial Description

The study is being done to examine the effects of a medication called mifepristone in children with Cushing's disease. Since a child's body may absorb and use mifepristone in a different way than adults, it is important to have information about the amount of mifepristone to give children and what will happen to it. Mifepristone has been FDA approved for use only in adults with Cushing's syndrome, and it is important to learn if mifepristone improves the symptoms and signs of Cushing's disease in children. The study is limited to children with Cushing's syndrome due to a pituitary tumor (Cushing's disease) and will not enroll children with Cushing's syndrome due to other causes. The study will investigate how children's bodies absorb and process mifepristone, how it works in children and what effect it has on the use of sugar in the body, on the child's weight and on growth hormone. An important part of the study is to evaluate the side effects of mifepristone in children. ;

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01925092
Study type	Interventional
Source	Corcept Therapeutics
Contact
Status	Withdrawn
Phase	Phase 3
Start date	August 2013

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00881283` - Long-term Cardiovascular Risk in Cured Cushing's Patients
Completed	`NCT02568982` - Cushing's Disease Complications
Completed	`NCT02697734` - Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease	Phase 3
Completed	`NCT01374906` - Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease	Phase 3
Recruiting	`NCT03364803` - Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Not yet recruiting	`NCT02603653` - Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease	N/A
Completed	`NCT01371565` - Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome	Phase 3
Recruiting	`NCT00845351` - Preoperative Bexarotene Treatment for Cushing's Disease	Phase 1/Phase 2
Completed	`NCT00889525` - Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor	Phase 3
Completed	`NCT02060383` - Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly	Phase 4
Recruiting	`NCT03474601` - Seoul National University Pituitary Disease Cohort Study
Recruiting	`NCT04339751` - Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease	Phase 2
Not yet recruiting	`NCT04569591` - Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease	N/A
Recruiting	`NCT02484755` - Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease	Phase 2
Active, not recruiting	`NCT01794793` - Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies	Phase 4
Completed	`NCT00434148` - Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease	Phase 3
Completed	`NCT03346954` - Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease	N/A
Completed	`NCT01582061` - An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.	Phase 3
Recruiting	`NCT03708900` - Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease	Phase 2
Terminated	`NCT00612066` - Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)	Phase 2